

Immacolata Brigida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2556498/publications.pdf>

Version: 2024-02-01

25
papers

2,522
citations

394421

19
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

3232
citing authors

#	ARTICLE	IF	CITATIONS
1	Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency. <i>European Journal of Immunology</i> , 2022, 52, 1171-1189.	2.9	9
2	A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. <i>Journal of Experimental Medicine</i> , 2019, 216, 2778-2799.	8.5	132
3	Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies. <i>Frontiers in Immunology</i> , 2019, 10, 316.	4.8	42
4	A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2296-2299.	2.9	87
5	Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. <i>Lancet Haematology</i> , 2019, 6, e239-e253.	4.6	166
6	T-cell defects in patients with ARPC1B germline mutations account for combined immunodeficiency. <i>Blood</i> , 2018, 132, 2362-2374.	1.4	99
7	First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. <i>Frontiers in Immunology</i> , 2018, 9, 113.	4.8	25
8	The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. <i>Clinical Immunology</i> , 2017, 178, 20-28.	3.2	31
9	Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. <i>Blood</i> , 2016, 128, 45-54.	1.4	173
10	A novel genomic inversion in Wiskott-Aldrich-associated autoinflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 619-622.e7.	2.9	15
11	B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 692-702.e2.	2.9	41
12	B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 799-806.e10.	2.9	30
13	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. <i>Clinical Immunology</i> , 2013, 146, 248-261.	3.2	186
14	Autoimmune Dysregulation and Purine Metabolism in Adenosine Deaminase Deficiency. <i>Frontiers in Immunology</i> , 2012, 3, 265.	4.8	102
15	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 1820-1830.	1.4	47
16	HIV-1 envelope-dependent restriction of CXCR4-using viruses in child but not adult untransformed CD4+ T-lymphocyte lines. <i>Blood</i> , 2012, 119, 2013-2023.	1.4	6
17	Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. <i>Blood</i> , 2012, 119, 1428-1439.	1.4	107
18	Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. <i>Journal of Clinical Investigation</i> , 2012, 122, 2141-2152.	8.2	55

#	ARTICLE	IF	CITATIONS
19	In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1368-1375.e8.	2.9	13
20	Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1417-1419.e3.	2.9	13
21	Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. <i>EMBO Molecular Medicine</i> , 2011, 3, 89-101.	6.9	95
22	Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2010, 10, 551-556.	2.3	56
23	Role of reduced intensity conditioning in T-cell and B-cell immune reconstitution after HLA-identical bone marrow transplantation in ADA-SCID. <i>Haematologica</i> , 2010, 95, 1778-1782.	3.5	16
24	Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID. <i>Immunologic Research</i> , 2009, 44, 150-159.	2.9	32
25	Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency. <i>New England Journal of Medicine</i> , 2009, 360, 447-458.	27.0	944